Peer-reviewed veterinary case report
Cryoprecipitate transfusions to stop bleeding in 21 dogs
By Lam, W Y Eunice et al.·Published in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)·2025·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective Evaluation of Cryoprecipitate Transfusion in Dogs to Prevent or Treat Hemorrhage: 21 Cases (2009-2023).
- Species:
- dog
Plain-English summary
A group of 21 dogs with bleeding disorders or at risk of bleeding received cryoprecipitate transfusions to help prevent or control hemorrhage. Most of these dogs had von Willebrand disease or hemophilia A, and some received additional blood products or medications. Fortunately, none of the dogs experienced serious side effects from the transfusions, and all were able to go home after a short hospital stay. While the study couldn't definitively prove the benefits of the treatment due to the complexity of each case, the transfusions appeared to be safe for the dogs involved.
People also search for: dog bleeding disorder treatment · cryoprecipitate transfusion for dogs · von Willebrand disease in dogs
Abstract
OBJECTIVE: To report homologous cryoprecipitate transfusions in dogs with hemostatic disorders, hemorrhage, or risk of hemorrhage, and to report adverse reactions associated with these cryoprecipitate transfusions. DESIGN: Retrospective case series (July 2009 to July 2023). SETTING: University teaching hospital. ANIMALS: Twenty-one client-owned dogs with hemostatic disorders, hemorrhage, or risk of procedure-related hemorrhage. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: All dogs received homologous cryoprecipitate transfusion. Sixteen dogs had von Willebrand disease (one also had factor XI deficiency); three dogs had hemophilia A; and two dogs had normal concentration of von Willebrand factor and were not diagnosed with any hemostatic disorder. Sixteen dogs also received other blood products and/or hemostatic medications. Twenty-two cryoprecipitate transfusions were administered to 16 dogs before, during, or after surgery; 16 of those 22 transfusions were given to 14 dogs without evidence of hemorrhage but with history of bleeding disorder and/or previous hemorrhage with the aim of preventing hemorrhage. Eight transfusions were given to six dogs to control hemorrhage not associated with surgery. Sixteen dogs (18 transfusions) received cryoprecipitate prepared in-house. Five dogs (12 transfusions) received a commercial lyophilized cryoprecipitate. No dog developed any serious adverse reactions to cryoprecipitate transfusion. All dogs were discharged from the hospital (median, 2 days after cryoprecipitate transfusion [range, 1-25 days]). The benefits of cryoprecipitate transfusion could not be well documented because of the retrospective nature of this study and the concurrent administration of other blood products and/or hemostatic medications to 16 dogs. CONCLUSIONS: Homologous cryoprecipitate transfusion appeared to be safe when administered for prevention or treatment of hemorrhage in dogs, but additional studies to assess safety and efficacy are warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41056368/